Navigation Links
Venaxis to Present at Three Upcoming Investor Conferences
Date:9/5/2013

CASTLE ROCK, Colo., Sept. 5, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 8 – 10, 2013, at the Millennium Broadway Hotel in New York, the Craig-Hallum 4th Annual Alpha Select Conference, to be held September 26, 2013, at the Convene 730 3rd Avenue in New York; as well as the Aegis Capital Vegas Healthcare Conference, to be held September 26 – 28, 2013, at the Wynn Las Vegas Hotel.Event:Rodman & Renshaw Annual Global Investment ConferenceDate: Monday, September 9, 2013 Time: 3:40 pm (Eastern Time) Location:Millennium Broadway Hotel; New York, NY 

Event:Craig-Hallum 4th Annual Alpha Select ConferenceDate: Thursday, September 26, 2013 Time: 3:10 pm (Eastern Time)Location:Flatiron Room; Convene 730 3rd Avenue; New York, NY 

Event:Aegis Capital Vegas Healthcare ConferenceDate: Thursday, September 26, 2013 Time: 11:30 am (Mountain Time) Location:Wynn Las Vegas Hotel; Las Vegas, NVSteve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business at the Rodman & Renshaw and Craig-Hallum Conferences, and Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, will present at the Aegis Capital Conference. Mr. Lundy and Mr. Hurd will be available to participate in one-on-one meetings with investors who are registered to attend the respective conferences. 

The Rodman & Renshaw presentation will be webcast. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast replay will remain available for 90 days following each live presentation.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD 
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda 
csojda@tiberend.com; (212) 375-2686


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference
2. Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Venaxis to Present at 25th Annual ROTH Conference
5. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
6. Venaxis to Present at 2013 BIO CEO and Investor Conference
7. AspenBio Pharma Changes Company Name to Venaxis, Inc.
8. Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
10. Lexicon To Present At The Morgan Stanley Global Healthcare Conference
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
Breaking Medicine News(10 mins):